Navigation Links
Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
Date:5/12/2010

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2010.

"We have recently seen a range of preclinical and clinical results that both improved our understanding of REOLYSIN(R)'s mechanism of action and provided evidence of synergies with currently approved therapeutics in an expanded range of potential indications," said Dr. Brad Thompson, President and CEO of Oncolytics. "While much of this information will support future decisions with respect to our evolving clinical program, our near term focus will be on completing the final preparations to begin enrollment in our Phase III trial which we expect to begin in the second quarter."

    Selected Highlights
    -------------------

    Since January 1, 2010 the Company announced:

    Clinical Trial Results

    -   A poster presentation, entitled "Reovirus replication in ovarian and
        peritoneal tumors after intravenous administration," covering
        correlative results from a Phase 1/2 study with reovirus, sponsored
        by the National Cancer Institute under its Clinical Trials Agreement
        with Oncolytics, in patients with ovarian, primary peritoneal and
        fallopian tube carcinoma, was presented at the 101st AACR Annual
        Meeting in Washington, DC. The authors reported that when REOLYSIN is
        administered intravenously, the reovirus can be demonstrated to
        localize and replicate in ovarian and peritoneal tumors;

    Clinical Program

    -   Approval from the U.K. Medicines and Healthcare products Regulatory
        Age
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ...
(Date:12/24/2014)... expects global cell isolation and expansion market to grow at ... about the vital drivers, restraints, trends, opportunities, strategies and challenges ... http://bit.ly/1yUxy0T , According to the report, the global market ... CAGR during near future. It expects this growth to be ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... reporting system for studying NFAT activation , ... Chao-Feng Zheng ,Stratagene , Stratagenes new PathDetect ... designed for studying the activation of the,nuclear factor ... which play an essential role in inducible gene ...
... of your choice , , ... Inc. , The PathDetect in vivo signal ... the in vivo activation of signal transduction,pathways. ... fusion trans-activator,plasmid that expresses pathway-specific trans-activator proteins ...
... Mycoplasma PCR Primer Set for fast and easy detection ... ,Yale University , D. R. Staggs ,Genetic Applications LLC ... cell cultures can substantially,reduce the potency of transfection reagents. ... the optimal amounts of LipoTAXI ...
Cached Biology Technology:Cis-Reporting System Monitors Intracellular Calcium Mobilization 2Cis-Reporting System Monitors Intracellular Calcium Mobilization 3Cis-Reporting System Monitors Intracellular Calcium Mobilization 4Cis-Reporting System Monitors Intracellular Calcium Mobilization 5New Fusion Trans-Activator Plasmids for Studying Signal Transduction,Pathways 2New Fusion Trans-Activator Plasmids for Studying Signal Transduction,Pathways 3New Fusion Trans-Activator Plasmids for Studying Signal Transduction,Pathways 4New Fusion Trans-Activator Plasmids for Studying Signal Transduction,Pathways 5New Fusion Trans-Activator Plasmids for Studying Signal Transduction,Pathways 6Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center today ... School of Medicine. Funding for this $50 million capital project ... publicly launched next summer. The medical education ... Reynolds Tobacco Company complex, adjacent to 525@vine in Wake Forest ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... School Team 1 won the Colorado High School Science Bowl ... Bowl in Washington D.C., Apr. 25-29, where they will compete ... 70 high schools. The U.S. Department of Energy (DOE) ... to encourage high school students to explore math and science. ...
... second trimester markers for Down,s syndrome that are detected by ... Ultrasound in Obstetrics & Gynecology , the study,s results ... with the condition. Screening for Down,s syndrome is offered ... risk based on their age. Certain features detected during a ...
... when females choose to mate with more than one ... a team of scientists from Queen Mary, University of London, ... active role in selecting their mates, with a consistent proportion ... males each year. "Until now there has been ...
Cached Biology News:Study reveals significance of second trimester markers for Down's syndrome 2Female deer take control during the mating season 2
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
... Immunogen: Synthetic peptide derived from ... mouse and rat LRP5. ... mouse LRP5 proteins. Reactivity: ... LRP5-pSEC-tag-transfected 293T cells MCF-7 T47D ...
Replacement Parts for Electrophoresis Apparatus...
...
Biology Products: